Westover Capital Advisors LLC Makes New Investment in Merck & Co., Inc. $MRK

Westover Capital Advisors LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, Holdings Channel reports. The institutional investor bought 5,650 shares of the company’s stock, valued at approximately $595,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the last quarter. Tucker Asset Management LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $34,000. Entrust Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $37,000. Finally, United Financial Planning Group LLC bought a new position in shares of Merck & Co., Inc. in the 3rd quarter valued at $31,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $122.55 on Monday. The company has a market capitalization of $302.67 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 2.76 and a beta of 0.18. Merck & Co., Inc. has a twelve month low of $75.40 and a twelve month high of $125.14. The stock has a fifty day simple moving average of $115.92 and a 200 day simple moving average of $110.41. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Sichuan Kelun-Biotech reported encouraging late-stage lung cancer data for a Keytruda combination, with the treatment beating Keytruda alone and improving confidence in Merck’s cancer pipeline. Kelun, Merck’s lung cancer combo improves survival in late-stage China trial
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion for Keytruda plus Padcev as a perioperative treatment for certain bladder cancer patients, which could expand the drug pair’s commercial reach if formally approved. Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev
• Positive Sentiment: Additional coverage highlighted positive EU recommendations and trial momentum across Merck’s oncology portfolio, suggesting the company is building new growth drivers ahead of future Keytruda patent pressure. Merck stock jumps as Keytruda combo trials boost cancer pipeline
• Neutral Sentiment: Some commentary noted Gardasil sales remain weak due to soft demand in China and other markets, which is a reminder that Merck still has headwinds outside oncology. Will Weak Gardasil Sales Continue to Ail MRK’s Vaccines Sales in 2026?
• Neutral Sentiment: Merck’s recent run-up also reflects broader investor optimism after strong quarterly results and improving sentiment around its pipeline, rather than a single one-day event. Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Analyst Upgrades and Downgrades

MRK has been the subject of a number of research reports. Wells Fargo & Company dropped their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Friday, February 13th. Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Finally, JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.